The newsletter for doctors
January 21, 2022
Neuro nutshell series has discussed few sections. The first section covers an analysis on the clinical response of add-on Brivaracetam therapy in patients with focal epilepsy. Conclusively, it was inferred that Brivaracetam is effective and well-tolerated add-on therapy in seizure control in patients with focal epilepsy.
The next section of conference update covers a 34th International Epilepsy Congress that held on August 28th – September 1st, 2021. In this, Ryvlin P et al highlighted the tolerability and efficacy of Brivaracetam in patients taking 1 or 2 concomitant AEDs. It was postulated that the therapeutic doses of BRV were effective and well-tolerated regardless of concomitant AEDs in patients with focal epilepsy.
Another section is on a portable, low-field MRI device that can aid in the detection of intracranial hemorrhage (ICH) right at the patient’s bedside. Researchers stated that this type of device would be especially useful in rural areas of the country and local hospitals because “there are a variety of brain conditions, stroke, head trauma, brain infection, brain tumors, the operating room, and all kinds of neurological conditions” where portable MRI could be useful. Lastly, a computational analysis of multimodal MRI data in detecting covert abnormalities in patients with refractory focal epilepsy has been covered.
Nutshell | The newslettter for doctors